Prelude Therapeutics Statistics Share Statistics Prelude Therapeutics has 76.09M
shares outstanding. The number of shares has increased by 2.6%
in one year.
Shares Outstanding 76.09M Shares Change (YoY) 2.6% Shares Change (QoQ) 2.35% Owned by Institutions (%) 37.34% Shares Floating 42.47M Failed to Deliver (FTD) Shares 1,077 FTD / Avg. Volume 0.66%
Short Selling Information The latest short interest is 520.77K, so 0.92% of the outstanding
shares have been sold short.
Short Interest 520.77K Short % of Shares Out 0.92% Short % of Float 7.06% Short Ratio (days to cover) 4.95
Valuation Ratios The PE ratio is -0.76 and the forward
PE ratio is -0.72.
Prelude Therapeutics's PEG ratio is
0.04.
PE Ratio -0.76 Forward PE -0.72 PS Ratio 13.75 Forward PS 5.5 PB Ratio 0.73 P/FCF Ratio -0.93 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Prelude Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.3,
with a Debt / Equity ratio of 0.14.
Current Ratio 5.3 Quick Ratio 5.3 Debt / Equity 0.14 Debt / EBITDA -0.13 Debt / FCF -0.17 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $53.44K Profits Per Employee $-970.79K Employee Count 131 Asset Turnover 0.04 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -82.74% in the
last 52 weeks. The beta is 1.21, so Prelude Therapeutics's
price volatility has been higher than the market average.
Beta 1.21 52-Week Price Change -82.74% 50-Day Moving Average 0.88 200-Day Moving Average 0.95 Relative Strength Index (RSI) 51.02 Average Volume (20 Days) 163,895
Income Statement In the last 12 months, Prelude Therapeutics had revenue of 7M
and earned -127.17M
in profits. Earnings per share was -1.68.
Revenue 7M Gross Profit 7M Operating Income -139.71M Net Income -127.17M EBITDA -139.71M EBIT -139.71M Earnings Per Share (EPS) -1.68
Full Income Statement Balance Sheet The company has 12.47M in cash and 18.02M in
debt, giving a net cash position of -5.55M.
Cash & Cash Equivalents 12.47M Total Debt 18.02M Net Cash -5.55M Retained Earnings -583.56M Total Assets 141.26M Working Capital 82.62M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -102.89M
and capital expenditures -764K, giving a free cash flow of -103.65M.
Operating Cash Flow -102.89M Capital Expenditures -764K Free Cash Flow -103.65M FCF Per Share -1.37
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -1995.91% and -1816.76%.
Gross Margin 100% Operating Margin -1995.91% Pretax Margin -1816.76% Profit Margin -1816.76% EBITDA Margin -1995.91% EBIT Margin -1995.91% FCF Margin -1480.74%
